The syntheses of novel spin-labeled analogues of butaclamol, a spin-labeled phenylaziridinium and two amino derivatives of butaclamol, are presented. Preliminary results of in vitro activity of these compounds on dopaminergie, serotoninergic, and adrenergic receptors correlate with the importance of the previously proposed lipophilic accessory binding site in CNS dopamine receptor.